Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q3 2025 · 10-Q
Revenue$0.00$0.00derivedno prior Q3 2024 on file Net Income$48.40M$48.40MN/M vs Q3 2024 EPS Diluted$1.13$1.13N/M vs Q3 2024 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
Operating Income-$2,427,000N/M Operating Cash Flowderived-$1,625,000N/M Free Cash Flowderived-$1,625,000N/M ended Sep 30, 2025 · filed Nov 13, 2025 · 44 d after period end